• Jiang Fei
  • Executive Director
  • Guijing Capital

Curriculum Vitae


Ph.D., CHEMICAL ENGINEERING, Syracuse University in Syracuse, New York, United States (2006)
B.Sc., CHEMICAL ENGINEERING, East China University of Science & Technology in Shanghai, China (1998)

Professional Experience

Cell Genesys Inc. Process Development Scientist (2007-2009)
AlphaVax Inc. Process Development Engineer (2009-2010)
3SBio Inc. R&D Director (2010-2013)
3SBio Inc. Business Development Director (2013-2017)
Guijing Capital, Executive Director (2017-current)

Research Interests

Biopharmaceuticals and biotechnology

Honors & Awards



The regulatory reform and the trend of pharmaceutical industry in China

In the past several years, we noticed that China FDA (CFDA) started to implement comprehensive reforms to the review and approval system for drugs and medical devices. These reforms are aimed to enhance quality of review and approval, eliminate backlog of regulatory applications, and encourage research and development of innovative new drugs. Should these changes come to pass, the opportunities for the pharmaceutical industry in China will be huge. The market, which is forecast to grow to as much as $167 billion by 2020, is experiencing near-double digit annual growth. Already, the cross-border transactions deal in China are booming, mainly to introduce novel drug candidates into China’s market. We will discuss the CFDA reform and the trend of pharmceutical industry in the future.